Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Aug 4;14:4677. doi: 10.1038/s41467-023-39571-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 8 — a SLC25A22 knockout synergized with anti-PD1 in suppressing the growth of CT26 allografts (n = 10) and b MC38-Kras^G12V allografts (n = 8). Each dot represents an independent tumor. c CD8⁺ T-cell and IFN-γ expression was induced by combined SLC25A22 knockout and anti-PD1, whilst MDSC infiltration was reduced by the combination of SLC25A22 knockout plus anti-PD1 therapy in CT26 allografts (n = 5) and d MC38-Kras^G12V allografts (n = 8). Each dot represents an independent tumor. e siSlc25a22-encapsulated nanoparticles (VNP-siSLC25A22) synergized with anti-PD1 to suppress MC38-Kras^G12V allografts growth and increased CD8⁺ T-cell activation (n = 10) and f their effect on IFN-γ levels on CD8⁺ T cells (siNC+IgG and siSLC+IgG: n = 10 per group; siNC+Anti-PD1 and siSLC+ Anti-PD1: n = 9 per group). Each dot represents an independent tumor. g The overall graphical summary of the study (Created with BioRender.com). Data are presented as mean ± SEM for growth curve (a, b, e) and ± SD for others (a–f). Two-tailed two-way ANOVA for growth curve comparison (a, b, e). Two-tailed Student’s t test for two-group comparison (a, c). Two-tailed Mann–Whitney U test for two-group comparison (b, d–f). ns, no significance. Source data are provided as a Source Data file.